Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Spyre Therapeutics (SYRE) Debt Ratio (2023 - 2025)

Spyre Therapeutics (SYRE) has disclosed Debt Ratio for 3 consecutive years, with 0.03 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Debt Ratio fell 28.82% year-over-year to 0.03, compared with a TTM value of 0.03 through Dec 2025, down 28.82%, and an annual FY2025 reading of 0.03, down 28.82% over the prior year.
  • Debt Ratio was 0.03 for Q4 2025 at Spyre Therapeutics, up from 0.02 in the prior quarter.
  • Across five years, Debt Ratio topped out at 0.67 in Q2 2023 and bottomed at 0.0 in Q4 2023.
  • Average Debt Ratio over 3 years is 0.1, with a median of 0.04 recorded in 2023.
  • The sharpest move saw Debt Ratio crashed 99.1% in 2024, then surged 1736.21% in 2025.
  • Year by year, Debt Ratio stood at 0.0 in 2023, then surged by 913.7% to 0.04 in 2024, then fell by 28.82% to 0.03 in 2025.
  • Business Quant data shows Debt Ratio for SYRE at 0.03 in Q4 2025, 0.02 in Q3 2025, and 0.11 in Q2 2025.